These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9336327

  • 1. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
    Johansson L, Sohn D, Thorberg SO, Jackson DM, Kelder D, Larsson LG, Rényi L, Ross SB, Wallsten C, Eriksson H, Hu PS, Jerning E, Mohell N, Westlind-Danielsson A.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):216-25. PubMed ID: 9336327
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, Sommermeyer H, Glaser T.
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
    [Abstract] [Full Text] [Related]

  • 3. Electrophysiological comparison of 5-Hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing.
    Martin LP, Jackson DM, Wallsten C, Waszczak BL.
    J Pharmacol Exp Ther; 1999 Feb; 288(2):820-6. PubMed ID: 9918594
    [Abstract] [Full Text] [Related]

  • 4. Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181.
    Hillegaart V, Ahlenius S.
    Br J Pharmacol; 1998 Dec; 125(8):1733-43. PubMed ID: 9886765
    [Abstract] [Full Text] [Related]

  • 5. The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist.
    Rënyi L, Evenden JL, Fowler CJ, Jerning E, Kelder D, Lake-Bakaar D, Larsson LG, Mohell N, Sällemark M, Ross SB.
    J Pharmacol Exp Ther; 2001 Dec; 299(3):883-93. PubMed ID: 11714872
    [Abstract] [Full Text] [Related]

  • 6. MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors.
    Przegaliński E, Filip M, Bijak M, Wedzony K, Budziszewska B, Tokarski K, Maćkowiak M, Fijał K.
    Pol J Pharmacol; 1996 Dec; 48(1):13-22. PubMed ID: 9112623
    [Abstract] [Full Text] [Related]

  • 7. S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors.
    Millan MJ, Rivet JM, Canton H, Lejeune F, Bervoets K, Brocco M, Gobert A, Lefebvre de Ladonchamps B, Le Marouille-Girardon S, Verriele L.
    J Pharmacol Exp Ther; 1992 Aug; 262(2):451-63. PubMed ID: 1323650
    [Abstract] [Full Text] [Related]

  • 8. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
    Chojnacka-Wójcik E, Kłodzińska A, Tatarczyńska E, Paluchowska MH.
    Pol J Pharmacol; 1999 Aug; 51(5):405-13. PubMed ID: 10817541
    [Abstract] [Full Text] [Related]

  • 9. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
    de Boer SF, Lesourd M, Mocaer E, Koolhaas JM.
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1125-33. PubMed ID: 10027850
    [Abstract] [Full Text] [Related]

  • 10. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
    Millan MJ, Canton H, Gobert A, Lejeune F, Rivet JM, Bervoets K, Brocco M, Widdowson P, Mennini T, Audinot V.
    J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
    [Abstract] [Full Text] [Related]

  • 11. Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain.
    Corradetti R, Laaris N, Hanoun N, Laporte AM, Le Poul E, Hamon M, Lanfumey L.
    Br J Pharmacol; 1998 Feb; 123(3):449-62. PubMed ID: 9504386
    [Abstract] [Full Text] [Related]

  • 12. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [Abstract] [Full Text] [Related]

  • 13. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
    Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC, Jacobs BL.
    J Pharmacol Exp Ther; 1996 Aug; 278(2):752-62. PubMed ID: 8768728
    [Abstract] [Full Text] [Related]

  • 14. The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats.
    Lindström E, Ravnefjord A, Brusberg M, Hjorth S, Larsson H, Martinez V.
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1048-55. PubMed ID: 19325032
    [Abstract] [Full Text] [Related]

  • 15. Two selective 5-HT1A receptor antagonists, WAY-100 635 and NDL-249, stimulate locomotion in rats acclimatised to their environment and alter their behaviour: a behavioural analysis.
    Jackson DM, Wallsten CE, Jerning E, Hu PS, Deveney AM.
    Psychopharmacology (Berl); 1998 Oct; 139(4):300-10. PubMed ID: 9809851
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects.
    Björk L, Cornfield LJ, Nelson DL, Hillver SE, Andén NE, Lewander T, Hacksell U.
    J Pharmacol Exp Ther; 1991 Jul 01; 258(1):58-65. PubMed ID: 1830099
    [Abstract] [Full Text] [Related]

  • 17. Nad-299 antagonises 5-HT-stimulated and spiperone-inhibited [35S]GTPgammaS binding in cloned 5-HT1A receptors.
    Jerning E, Rosqvist S, Mohell N.
    J Recept Signal Transduct Res; 2002 Jul 01; 22(1-4):483-95. PubMed ID: 12503636
    [Abstract] [Full Text] [Related]

  • 18. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.
    Millan MJ, Rivet JM, Canton H, Le Marouille-Girardon S, Gobert A.
    J Pharmacol Exp Ther; 1993 Mar 01; 264(3):1364-76. PubMed ID: 8450471
    [Abstract] [Full Text] [Related]

  • 19. Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.
    Jerning E, Svantesson GT, Mohell N.
    Eur J Pharmacol; 1998 Nov 06; 360(2-3):219-25. PubMed ID: 9851589
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
    López-Rodríguez ML, Rosado ML, Benhamú B, Morcillo MJ, Sanz AM, Orensanz L, Beneitez ME, Fuentes JA, Manzanares J.
    J Med Chem; 1996 Oct 25; 39(22):4439-50. PubMed ID: 8893838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.